By PAM BELLUCK
The drug maker said the drug, solanezumab, had not helped patients with mild symptoms of the disease, a result that may affect prospects for similar tests underway.
Published: November 22, 2016 at 07:00PM
from NYT Health http://ift.tt/2ggYmuh
via IFTTT
from WordPress http://ift.tt/2glZOsT
via IFTTT
No comments:
Post a Comment